Brainstorms Abound At NIH's Neurological And Stroke Institute

Research in the neurosciences is in the midst of a particularly exciting period of discovery, says Zach Hall, director of the National Institute of Neurological Disorders and Stroke (NINDS), as scientists continue to learn more about the basic biology of such disorders as stroke, epilepsy, and degenerative conditions like Parkinson's, Alzheimer's, and Huntington's diseases. Hall's institute has supported and participated in many of these landmark studies. Now the field stands poised on the brin

Written byNeeraja Sankaran
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Research in the neurosciences is in the midst of a particularly exciting period of discovery, says Zach Hall, director of the National Institute of Neurological Disorders and Stroke (NINDS), as scientists continue to learn more about the basic biology of such disorders as stroke, epilepsy, and degenerative conditions like Parkinson's, Alzheimer's, and Huntington's diseases.

Hall's institute has supported and participated in many of these landmark studies. Now the field stands poised on the brink of another, equally fruitful era, as investigators are turning their attention to ways of treating or preventing these maladies.

"Until now, all the major achievements in neurology were in diagnosis, but that is about to change," he predicts. "Because of the development of various molecular and cellular tools, and imaging technologies, we are going to be able to think about developing strategies for their treatment."

First established in 1950 as the National Institute of Neurological Diseases ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies